(Q44004705)

28 November 2017

Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors (English)

1 reference

28 November 2017

Britta Maurer

1

1 reference

28 November 2017

Alfiya Distler

2

1 reference

28 November 2017

Clara Dees

3

1 reference

28 November 2017

Korsa Khan

4

1 reference

28 November 2017

Christopher P Denton

5

1 reference

28 November 2017

David Abraham

6

1 reference

28 November 2017

Renate E Gay

7

1 reference

28 November 2017

Beat A Michel

8

1 reference

28 November 2017

Steffen Gay

9

1 reference

28 November 2017

Jörg Hw Distler

10

1 reference

28 November 2017

Oliver Distler

11

1 reference

28 November 2017

language of work or name

English

0 references

publication date

7 September 2013

1 reference

Annals of the Rheumatic Diseases

28 November 2017

1 reference

28 November 2017

72

1 reference

28 November 2017

12

1 reference

28 November 2017

2039-2046

1 reference

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

28 November 2017

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203729

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203729

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203729

Innovative antifibrotic therapies in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203729

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203729

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203729

Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203729

The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203729

Criteria to select molecular targets for anti-fibrotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203729

Molecular framework for response to imatinib mesylate in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203729

A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203729

Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203729

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203729

10.1136/ANNRHEUMDIS-2013-203729

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference